±ÙÀ§Ãà¼ºÃø»ö°æÈ­Áõ ½ÃÀå : KOL ÀλçÀÌÆ®
Amyotrophic Lateral Sclerosis - KOL Insight
»óǰÄÚµå : 1507968
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 39,950 £Ü 57,803,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±ÙÀ§Ãà¼ºÃø»ö°æÈ­Áõ(ALS) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í Sanofi RilutekÀÌ ´ã´çÇÏ´Â ±âÃÊÀû ¿ªÇÒºÎÅÍ SOD1-ALS¿¡ ´ëÇÑ Biogen/IonisÀÇ QalsodyÀÇ À¯¸ÁÇÑ °¡´É¼º, FUS º¯ÀÌÇü ALS¿¡ ´ëÇÑ IonisÀÇ ulefnersen¸¦ µÑ·¯½Ñ ³«°ü·Ð±îÁö ALS Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â Àü·«Àû µ¿ÇâÀ» »ìÆìº¾´Ï´Ù. ¶ÇÇÑ ÁøÈ­ÇÏ´Â ALS Ä¡·á Àü¸ÁÀ» »ó¼¼È÷ ºÐ¼®Çϰí, ALS Ä¡·áÀÇ Áøº¸¸¦ À§ÇÑ ÁÖ¿ä ±âȸ¿Í °úÁ¦¸¦ °­Á¶ÇÕ´Ï´Ù.

¸ñÂ÷

°³¿ä

ÇöÀç ¹× ÇâÈÄ Ä¡·á ¾Ë°í¸®Áò

Á¶»ç ¸ñÀû

½ÂÀÎ ÀǾàǰ

ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦

ÇâÈÄ Ä¡·á µ¿Çâ

ºÎ·Ï

KOL º¸°í¼­

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

From the foundational role of Sanofi's Rilutek, the promising potential of Biogen/Ionis' Qalsody for SOD1-ALS, to the optimism surrounding Ionis' ulefnersen for FUS-mutated ALS, uncover the strategic trends shaping the future of ALS treatment. This report provides an in-depth analysis of the evolving therapeutic landscape, highlighting key opportunities and challenges in advancing ALS care. Explore the strategic implications for drug development, market dynamics, and patient care strategies.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Approved drugs

Pipeline drugs

Future treatment trends

Appendix

KOL Bulletins

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â